Tracon Pharmaceuticals price target lowered to $6 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Tracon Pharmaceuticals to $6 from $7 and keeps a Buy rating on the shares following the Q4 report. The analyst cites dilution from the increased share count for the target drop.